People: Novozymes A/S (NZYMb.CO)

NZYMb.CO on Copenhagen Stock Exchange

264.80DKK
7:51am EST
Price Change (% chg)

kr.-7.60 (-2.79%)
Prev Close
kr.272.40
Open
kr.272.00
Day's High
kr.272.00
Day's Low
kr.264.40
Volume
310,199
Avg. Vol
512,463
52-wk High
kr.283.60
52-wk Low
kr.204.40

Search Stocks

Summary

Name Age Since Current Position

Henrik Gurtler

60 2000 Chairman of the Board

Peder Holk Nielsen

57 2013 President, Chief Executive Officer

Agnete Raaschou-Nielsen

57 2014 Independent Vice Chairman of the Board

Benny Loft

49 2013 Executive Vice President of Corporate Functions, Chief Financial Officer

Per Falholt

55 Executive Vice President of Research and Development, Chief Scientific Officer

Andrew Fordyce

51 2013 Executive Vice President of Business Operations

Thomas Nagy

50 2013 Executive Vice President of Supply Operations

Thomas Videbaek

53 2013 Executive Vice President of Business Development

Lena Bech Halskov

47 2013 Director, Employee Representative

Lars Green

47 2014 Director

Anders Hentze Knudsen

55 2013 Director, Employee Representative

Joergen Buhl Rasmussen

59 2011 Independent Director

Lars Koeppler

52 2010 Independent Director, Employee Representative

Lena Olving

58 2011 Independent Director

Mathias Uhlen

60 2007 Independent Director

Thomas Bomhoff

Head of Investor Relations

Biographies

Name Description

Henrik Gurtler

Mr. Henrik Gurtler has served as Chairman of the Board of Directors at Novozymes A/S since 2000. He is also Chief Executive Officer at Novo A/S. He serves as Chairman of the Board of Directors of Copenhagen Airports A/S (Koebenhavns Lufthavne A/S). He is Member of the Board of Directors of Novo Nordisk A/S. He has experience in managing and working in an international biotechnology company. He holds a Master of Science degree in Chemical Engineering from Danmarks Tekniske Universitet (Technical University of Denmark) from 1976.

Peder Holk Nielsen

Mr. Peder Holk Nielsen has been appointed President and Chief Executive Officer (CEO) of Novozymes A/S effective from April 1, 2013. Previously, he served as Executive Vice President of Enzyme Business at the Company from 2007 and as Executive Vice President of Business Operations from 2000. He is also Member of the Board of Directors at Hempel A/S, LEO Pharma A/S and Beta Renewables S.p.A. He is also Member of the Audit Committee at Betea Renewables S.p.A. He joined Novo A/S in 1984 as Product Manager of Enzymes Division. In 1987, he became Head of the New Business Development Group. He took over as Vice President in Research & Development in the Enzyme Process Division in 1990. In 1995, he joined the management team of the enzyme business in Novo Nordisk A/S initially as head of Development and Quality Management, and from 1999 he led Sales and Marketing in the enzymes business. He held this position until the demerger of Novozymes from Novo Nordisk. With the creation of Novozymes in 2000, he continued running the operational side of the business as Executive Vice President, responsible for Sales, Marketing and Supply Chain activities. In 2007, he assumed responsibility for all of Enzyme Business, including production, procurement, development and quality management. He holds a Master of Science degree in Chemical Engineering from the Technical University of Denmark (Danmarks Tekniske Universitet) from 1981, and a Doctorate of Philosophy degree from the Institute of Chemical Engineering at the Technical University of Denmark from 1984. He also holds a Bachelor of Commerce degree in International Business Management from the Copenhagen Business School from 1985.

Agnete Raaschou-Nielsen

Ms. Agnete Raaschou-Nielsen has served as Independent Vice Chairman of the Board of Directors at Novozymes A/S since February 26, 2014. She has been Independent Member of the Board of Directors of the Company since March 1, 2011. She is also Member of the Company's Audit Committee. She is also Chairman of the Board of Directors at Brdr. Hartmann A/S, Arkil Holding A/S and Pension Fund for Danish Lawyers and Economists, and Deputy Chairman of the Board of Directors at Danske Invest. She acts as Member of the Boards of Directors at Danske Invest Management A/S, Dalhoff Larsen & Horneman A/S, Solar A/S, and Aktieselskabet Schouw & Co. She has competencies in business development and acquisitions, macroeconomics and intellectual property rights.

Benny Loft

Mr. Benny D. Loft has been appointed Executive Vice President of Corporate Functions and Chief Financial Officer at Novozymes A/S, effective as of April 1, 2013. Before that, he has serves as Executive Vice President and Chief Financial Officer at Novozymes A/S. Prior to joining Novo Nordisk in 1998, he spent a decade with Price Waterhouse, where he served as Consultant and Auditor for Novo Nordisk, among others. He joined Novo Nordisk in 1998 as Director for Consolidated Accounts, Group Taxation and Tax Planning, and Stocks and Production Economy. He was involved in the demerger of Novo Nordisk and Novozymes A/S. During the same period, he was responsible for building Novozymes A/S' finance department. He has served as Vice President for Finance at Novozymes, and has also worked within acquisitions and negotiations. He currently serves as Member of the Boards of Directors of New Xellia Group AS, The Blue Planet and DONG Energy A/S. He is also Member of the Audit Committee at DONG Energy A/S and New Xellia Group A/S. He holds a Master's degree in Accounting, Tax and Auditing from the Copenhagen Business School. He became State-Authorized Public Accountant in 1996.

Per Falholt

Mr. Per Falholt serves as Executive Vice President of Research and Development, and Chief Scientific Officer (CSO) at Novozymes A/S. He has also been Member of the Board of Directors at DHI Group since May 2011 and at ARTs Biologics A/S. He is Chairman of the Board of Technical University of Denmark (DTU). He has also been Chairman for the Young Scientists association in Denmark, Member of The Danish Council for Research Policy, and External Lecturer at IMD, Lausanne, for Executive Master of Business Administration. He joined Novo A/S in 1984 as Research Chemist in the Enzyme Research and Development pilot plant. He also held a number of managerial positions within the development of new products for the detergent industry until he joined the Enzyme Development and Applications division in 1995 as Director for Application Technology. In 1997, he took responsibility for the America application technology unit in Raleigh, the United States. In 1999, he took the position of Corporate Vice President with responsibility for Enzyme Development and Application, and in May 2000, he was appointed Corporate Vice President of the Enzyme Business Research and Development. In connection with the demerger of Novozymes from Novo Nordisk, he was given the title of Executive Vice President for Research and Development. Prior to joining Novo Nordisk, he worked at the Technical University of Denmark (Danmarks Tekniske Universitet - DTU), where he obtained Master of Science degree in Chemical Engineering in 1983. He also earned an honorary Professor title at The Institute for Systems Biology at DTU in June 2010.

Andrew Fordyce

Mr. Andrew Fordyce has been appointed Executive Vice President of Business Operations at Novozymes A/S effective from April 1, 2013. He was previously Vice President of Sales and Customer Solutions. Since joining the Company in 1993, he has held several positions in commercial operations, Research and Development and production in Denmark, Switzerland and the United States. He holds a Doctorate of Philosophy degree in Chemical Engineering from the University of Texas at Austin.

Thomas Nagy

Mr. Thomas Nagy has been appointed Executive Vice President of Supply Operations at Novozymes A/S, effective as of April 1, 2013. Before that, he has served as Executive Vice President of Stakeholder Relations and COS at the Company since October 2007. He is also Member of the Board of Directors of the Danish-American Business Forum and the American Chamber of Commerce in Denmark. At the Company, he is responsible for Corporate Positioning, Sustainability Development, Corporate People and Organization, and Facility Management. He joined the Company in 1986 as Chemical Engineer when Novozymes A/S was the enzyme division of Novo Nordisk A/S. Over the years, he gained international experience in Brazil and the United States. Prior to his current position, he was President of Novozymes North America Inc. from 2004 to 2007. He also held a number of technical and managerial positions within enzyme and insulin bulk production before being promoted to Vice President for Production Denmark and Global Procurement in 2000. He was also Member of the Executive Committee and Board of Directors of Biotechnology Industry Organization (BIO). He received his Bachelor of Science degree in Chemical Engineering from the Technical University in Copenhagen (Danmarks Tekniske Universitet) in 1985, and he is a graduate of Wharton School of Business AMP program in 2006. In addition, he completed a number of business and management programs.

Thomas Videbaek

Mr. Thomas Videbaek has been appointed Executive Vice President of Business Development at Novozymes A/S, effective as of April 1, 2013. Before that, he has served as Executive Vice President of BioBusiness at the Company since September 2007. He is also Member of the Board of Directors of Evolva AG. He joined Novo Nordisk as Chemist in 1988 in Technical Service, Textile Enzymes. From 1990 to 1991, he served as Business Development Manager for Textile in the United States, and was later appointed Global Marketing Manager for Textile. In 1995, he became Global Marketing Director for Starch, and in 1996, he also assumed responsibility for Food and Feed enzymes, and was appointed Director for Strategic Marketing, Food and Feed enzymes, where he became responsible for analyzing market possibilities and developing marketing strategies and plans for the food and feed industries. In 1998, he was appointed General Manager for Novozymes Switzerland, as well as Vice President for Cereal Food and Beverage Marketing. In 2003, he became Vice President for Supply Chain Operations with responsibility for establishing a global organization in charge of the supply chain at Novozymes. In 2005, he became Vice President for Sales and Customer Solutions with responsibility for the global Sales and Customer Solutions organization. He holds a Master's degree in Chemical Engineering degree from the Technical University of Denmark's (Danmarks Tekniske Universitet) Department of Nutrition and Biochemistry in Copenhagen from 1986, and a Doctorate of Philosophy degree from the Technical University of Denmark from 1990. He also holds a Bachelor of Commerce degree in International Business from the Copenhagen Business School from 1992.

Lena Bech Halskov

Ms. Lena Bech Halskov has been appointed Member of the Board of Directors, Employee Representative at Novozymes A/S, effective as of February 28, 2013. She is Safety Adviser.

Lars Green

Dr. Lars Hall Green, Ph.D. has been Member of the Board of Directors of Novozymes A/S since February 26, 2014. He is also Senior Vice President of Novo Nordisk A/S.

Anders Hentze Knudsen

Mr. Anders Hentze Knudsen has been appointed Member of the Board of Directors, Employee Representative at Novozymes A/S, effective as of February 28, 2013. He is Senior Operator.

Joergen Buhl Rasmussen

Mr. Joergen Buhl Rasmussen has served as Independent Member of the Board of Directors at Novozymes A/S since March 1, 2011. He is also President and Chief Executive Officer of Carlsberg A/S. He acts as Chairman of the Board of Directors at JSC Baltika Breweries and as Member of the Board of Directors at Carlsberg Breweries A/S and the Confederation of Danish Industry’s Permanent Committee on Business Policies. He has competencies in acquisitions, international business and management, specifically within sales, marketing, and branding.

Lars Koeppler

Mr. Lars Bo Koeppler has served as Independent Member of the Board of Directors, Employee Representative at Novozymes A/S since December 1, 2010. Previously, he was Member of the Company's Board of Directors until 2004. He is Technician.

Lena Olving

Ms. Lena Olving has served as Independent Member of the Board of Directors at Novozymes A/S since March 1, 2011. She is also Member of the Company's Audit Committee. She is President and Chief Executive Officer at Mycronic Mydata AB (publ.). She acts as Member of the Board of Directors and Member of the Audit Committee at SJ AB. She has competencies in financial and accounting matters, and experience in supply chain, process optimization and production.

Mathias Uhlen

Mr. Mathias Uhlen has served as Independent Member of the Board of Directors at Novozymes A/S since 2007. He is Professor at the Royal Institute of Technology (Kungliga Tekniska Hogskolan, KTH) in Stockholm, Sweden, and the Technical University of Denmark (Danmarks Tekniske Universitet, DTU). He is also Chairman of the Board of Directors at Antibodypedia AB and Atlas Antibodies AB, as well as Deputy Chairman of the Board of Directors at Affibody AB. He acts as Member of the Board of Directors at Alligator AB, Swetree Technologies AB and Bure Equity AB. He has experience in research and biotechnology.

Thomas Bomhoff

Basic Compensation

Name Fiscal Year Total

Henrik Gurtler

1,250,000

Peder Holk Nielsen

16,600,000

Agnete Raaschou-Nielsen

625,000

Benny Loft

11,800,000

Per Falholt

11,600,000

Andrew Fordyce

6,100,000

Thomas Nagy

11,800,000

Thomas Videbaek

11,900,000

Lena Bech Halskov

347,000

Lars Green

--

Anders Hentze Knudsen

347,000

Joergen Buhl Rasmussen

417,000

Lars Koeppler

417,000

Lena Olving

625,000

Mathias Uhlen

417,000

Thomas Bomhoff

--
As Of 30 Dec 2013
Search Stocks